Administration of the drug Opdivo by injection for kidney cancer is no less effective than intravenous administration. Research that will allow patients to receive cancer treatment in five minutes instead of an hour, including outside major hospitals, was unveiled at the Genitourinary Cancer Symposium. American Society of Clinical Oncology (ACS).
Opdivo (nivolumab) is a next-generation immunotherapy drug for the treatment of kidney cancer. In a new study, scientists compared the effectiveness of intravenous administration via drip and subcutaneous injection. The first method requires a hospital stay of at least an hour, and the injection takes no more than five minutes.
Different approaches were tested on 495 patients with metastatic kidney cancer treated at 73 different cancer centers. All received Opdivo for the first time during the study.
Daily blood levels of the drug were monitored for 28 days after dosing. No significant difference was found between injection and intravenous administration. Additionally, the percentage of patients who responded at least partially to the medication was approximately 24% among those receiving injections and 18% among those receiving IV. Progression-free survival was approximately 7.2 and 5.6 months, respectively.
The authors believe that patients can now receive treatment faster. This is especially important for those living far from hospitals and could reduce disparities between urban and rural patients.
The results should be considered preliminary until published in a peer-reviewed journal.
Previous scientists in the name Prostate cancer, which does not always need to be treated.
What are you thinking?
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.